ReviewClinical kidney journal2023
Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Pre-treatment cognitive impairment in patients with NSCLC: Prevalence and psychosocial factors.IBRO neuroscience reports · 2026Article
- Endurance training mitigates morphine-induced renal dysfunction in young and aged rats: involvement of oxidative stress, SIRT1, Klotho and TFAM.Biogerontology · 2026Article
- Anticholinergic Burden and Progression to Kidney Replacement Therapy.Kidney international reports · 2026Article
- Perceived knowledge, attitudes, and practices of healthcare professionals toward the use of noninvasive neuromodulation technology in the treatment of cognitive disorders.BMC psychiatry · 2026Article
- Chronic Kidney Disease Amplifies Gabapentin-Associated Dementia Risk in Non-Dialysis Patients: Findings Consistent with a Renal Pharmacokinetic Vulnerability.medRxiv : the preprint server for health sciences · 2026Article
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
- Frailty Syndrome and Cardiovascular Diseases in Older People.Healthcare (Basel, Switzerland) · 2025Article
- Break free from cognitive impairment: The magic of exercise-induced molecules.Brain, behavior, & immunity - health · 2025Review
- Cholinergic system in patients with chronic kidney disease: cognitive and renal implications.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Cognitive impairment 2 years after mild to severe SARS-CoV-2 infection in a population-based study with matched-comparison groups.Scientific reports · 2025Article
- Drug-Induced Cognitive Impairment.Drug safety · 2025Review
- Cognitive impairment in kidney transplanted patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- CONNECT: what has been done and what needs to be done.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Choline Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population.Geriatrics (Basel, Switzerland) · 2025Review
- Cognitive impairment in CKD patients: a guidance document by the CONNECT network.Clinical kidney journal · 2025Review
- The anticholinergic burden in patients with chronic kidney disease: Patterns, risk factors, and the link with cognitive impairment.Journal of the American Geriatrics Society · 2025Article
- Safety evaluation of cinacalcet: Signal mining and analysis of adverse events based on the FAERS database.PloS one · 2025Article
- Acute Effects of Unplanned and Planned Hop-Landing Training on Neurocognitive Function and Knee Biomechanics.Orthopaedic journal of sports medicine · 2025Article
- Gut-kidney-brain axis and daytime sleepiness in Parkinson's disease and chronic kidney disease: an expert narrative review.Frontiers in aging neuroscience · 2025Review
- Interventions to improve cognitive performance in chronic kidney disease: A scoping review.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.